trials
Marburg, October 13, 2020, AGCT tested its novel EGFR prototype kit together with a German cancer research institute and HistogeneX, a global CRO laboratory supporting diagnostic and clinical studies in oncology with headquarters in Antwerp/Belgium. The results with non-clinical human DNA samples demonstrate cyberPCR’s high sensitivity with extreme wildtype DNA background and its superiority in a head-to-head comparison with today’s standard assays for real-time PCR and digital PCR platforms.Dirk Loeffert, AGCT’s COO, who brings along almost 20 years of product development know-how from his former position at Qiagen, is verySEE DETAIL...